R-102444 is a serotonin 5-HT2 receptor antagonist which was under development for the treatment of peripheral arterial occlusive disorders and pancreatitis. It is a laurate (dodecanoate) ester prodrug of R-96544.

The drug has been found to inhibit serotonin-induced platelet aggregation and to have antithrombotic effects in preclinical research. The active form, R-96544, shows selectivity for the serotonin 5-HT2A receptor over other targets, including the serotonin 5-HT1, 5-HT2B, and 5-HT3 receptors as well as the dopamine D2 receptor and adrenergic receptors, among others. However, it also showed high affinity for the serotonin 5-HT2C receptor, which was about 4-fold less than for the serotonin 5-HT2A receptor.

R-102444 was developed by Daiichi Sankyo Company. It reached the preclinical research stage of development prior to its discontinuation. R-102444 was first described in the scientific literature by Naoki Tanaka and colleagues by 2000.

See also